This review summarizes galectin-mediated mechanisms in leukemia biology, evaluates the potential of galectin-targeted therapies and offers insights for the development of specific inhibitors of Gal-1, -3, and -9 to promote clinical management and treatment efficacy. This evidence concerns the gene LGALS1 and leukemia.